Eli Lilly won approval for its new migraine treatment Reyvow back in October, but it had to wait for Drug Enforcement Administration scheduling to launch—and now, it's ready to roll. The first-of-its-kind med for acute migraine offers relief within two hours, data show, but it'll soon face competition from the CGRP class that's now only cleared to prevent the painful episodes.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,